Organisation paid for research Program year 2024 Source: CMS Open Payments

Palm Beach Neurological Center

Neither a doctor nor a teaching hospital

Research payments

$1,294,349

375 payments

Through program year 2024, Palm Beach Neurological Center is reported as receiving $1,294,349 in research payments, across 375 payments.

By program year

4 rows
Year Kind Amount Payments
2024 Research $4,663 1
2021 Research $225 1
2020 Research $323,446 70
2019 Research $966,015 303

Breakdown

Who paid Research payments · program years 2019–2024
  1. Eisai Inc. $947,469 362 payments
  2. Novartis Pharmaceuticals Corporation $298,662 2 payments
  3. Amgen Inc. $41,024 6 payments
  4. Biogen, Inc. $5,169 2 payments
  5. Eli Lilly and Company $2,025 3 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $769,931 319 payments
  2. A Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad $298,662 2 payments
  3. A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $110,988 1 payment
  4. A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies $66,550 42 payments
  5. Phase 2 Episodic Migraine Prophylaxis EMP $41,024 6 payments
  6. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $4,663 1 payment
  7. Assessment of Safety, Tolerability and Efficacy of Ly3002813 Alone and in Combination With Ly3202626 in Early Symptomatic Alzheimers Disease $2,025 3 payments
  8. 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $506 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record